30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
It is associated with metabolic syndrome, incident diabetes, carotid atherosclerosis, and endothelial dysfunction, conditions that in turn are strongly linked with brain damage and cognitive impairment. 5 key findings →
Design: cross-sectional Participants: 766 Evidence: moderate
Full summary, score breakdown and related studies → Original source
IL-6, and, to a lesser degree, CRP levels were associated with WMH severity as well as global markers of brain atrophy. 4 key findings →
Design: cross-sectional Participants: 1,316 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Hyperhomocysteinemia is associated with an increased risk of vascular disease, and recent results suggest that it also could increase the risk of dementia. 4 key findings →
Design: cross-sectional Participants: 1,241 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among 251 patients examined 3 months after the onset of acute ischemic stroke, we diagnosed dementia in 66 (26.3%) by using modified DSM-III-R criteria based on neuropsychological, neurological, functional, and psychiatric examinations. 4 key findings →
Design: cross-sectional Participants: 251 Evidence: low
Full summary, score breakdown and related studies → Original source
Cross-sectional analysis of CBF values was carried out among 668 volunteers and patients. 5 key findings →
Design: cross-sectional Participants: 230 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Blood-brain-barrier (BBB) dysfunction is a hallmark of aging and aging-related disorders, including cerebral small vessel disease and Alzheimer's disease. 4 key findings →
Design: cross-sectional Participants: 30 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Multiple MTHFR coding variants were identified in this small Indonesian VaD cohort. 2 key findings →
Design: cross-sectional Participants: 17 Evidence: moderate
Full summary, score breakdown and related studies → Original source
). Moreover, 12 proteins related to endothelial function and inflammation were associated with neuroimaging features of SVD. 4 key findings →
Design: cross-sectional Participants: 35 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants' median age was 70.7 years (Q1-Q3 = 67.8-74.0), with 52.4% being women. 5 key findings →
Design: cross-sectional Participants: 678 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
People with severe mental illnesses (SMIs), including schizophrenia spectrum disorders (SSD), major depressive disorder (MDD), and bipolar disorder (BD), experience elevated rates of physical comorbidity and premature mortality. 3 key findings →
Design: cross-sectional Participants: 694,086 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We assessed whether expansion size is associated with disease severity or phenotype. 4 key findings →
Design: cross-sectional Participants: 84 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Elevated cerebral Aβ level was associated with cholesterol fractions in a pattern analogous to that found in coronary artery disease. 5 key findings →
Design: cross-sectional Participants: 33 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Study objective Obstructive sleep apnea (OSA) contributes to the development of systemic hypertension, and hypertension strongly predicts the development of white matter change (WMC). 2 key findings →
Design: cross-sectional Participants: 289 Evidence: low
Full summary, score breakdown and related studies → Original source
Of 104 metabolites studied, glycodeoxycholic acid (GDCA) surpassed the false discovery rate and was associated the Alzheimer's Disease Assessment Scale-Cognitive Subscale version 13 (ADAS-Cog13) score (β = 0.12, 95 % CI = 0.05-0.20, p = 0.001) and cognitive impairment determined by mini-mental status exam (MMSE) (OR = 2.11, 95 % CI = 1.41-3.15, p < 0.001). 4 key findings →
Design: cross-sectional Participants: 578 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 261 patients (75.3±6.8 years) were recruited from a memory-clinic cohort. 5 key findings →
Design: cross-sectional Participants: 261 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Accumulating evidence implicates small vessel cerebrovascular disease, visualized as white matter hyperintensities (WMH) on T2-weighted magnetic resonance imaging, in the pathogenesis and diagnosis of Alzheimer's disease (AD). 2 key findings →
Design: cross-sectional Participants: 26 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Diabetes was not associated with brain atrophy cross-sectionally or longitudinally. 5 key findings →
Design: cross-sectional Participants: 112 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our aim is to examine the interplay between cerebral small vessel disease (CSVD) pathology, Alzheimer’s disease (AD) related amyloid-β (Aβ) clearance, and cognition in general population. 2 key findings →
Design: cross-sectional Participants: 1,026 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study included 3540 participants with RVC data and 489 with WMH data (median [IQR] age: 73.2 [71.4-76.3] and 72.5 [71.2-75.4] years; female: 52.9% and 47.6%) over a median follow-up of 7.4 [IQR 5.5-8.5] and 3.8 [IQR 2.9-5.3] years, respectively. 5 key findings →
Design: cross-sectional Participants: 3,540 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These cross-sectional results suggest that cortical changes (regional-specific damage and network breakdown), mediated (in)directly by WMH (tract-specific damage) and other factors (eg, vascular risk factors), might lead to cognitive decline. 5 key findings →
Design: cross-sectional Participants: 426 Evidence: low
Full summary, score breakdown and related studies → Original source
White matter hyperintensity (WMH), indicative of cerebral small vessel disease, has emerged as a potential biomarker for cognitive decline in Alzheimer's disease (AD). 2 key findings →
Design: cross-sectional Participants: 158 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our results pertaining to menopause-related characteristics, such as age at menopause or menopause hormonal therapy, did not replicate the literature reporting an association with WMH volumes. 5 key findings →
Design: cross-sectional Participants: 9,560 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cerebral small vessel disease (cSVD) is characterised by white matter hyperintensities (WMH) and contributes to stroke and dementia. 5 key findings →
Design: cross-sectional Participants: 60 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 225 patients (mean age 65.4 years, 54.2% male), MCR prevalence was 16.4%. 5 key findings →
Design: cross-sectional Participants: 225 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Although internal factors explain most about the poor nutritional status of aged residents in nursing homes, the factors related to nutritional care need further investigation to clarify their role in maintaining the nutritional status of aged residents. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events